This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Application based on results from the TROPION-Breast01 Phase III trial
The average time of dilation lasts three to eight hours
Subscribe To Our Newsletter & Stay Updated